Back to Directory
Alglucosidase Alfa
Performance & EnduranceEnzyme replacement therapy for Pompe disease, recombinant acid alpha-glucosidase.
Key Benefits
- ✓Treats Pompe disease
- ✓Improves motor function
- ✓Reduces cardiac involvement
- ✓Improves respiratory function
- ✓Enzyme replacement
Dosing Information
Dosage Range
20-40 mg/kg
Frequency
Every 2 weeks
Typical Duration
Lifelong
Detailed Protocol
Administered via intravenous infusion every 2 weeks. Infusion takes several hours. Premedication required. Lifelong therapy. Medical supervision.
About Alglucosidase Alfa
Alglucosidase alfa (Lumizyme, Myozyme) is recombinant human acid alpha-glucosidase (GAA) for Pompe disease enzyme replacement. Breaks down glycogen accumulation in lysosomes. FDA-approved for this rare neuromuscular disorder.
Research Notes
FDA-approved in 2006. Transformed Pompe disease treatment, particularly infantile-onset. High rate of antibodies limits efficacy in some patients. Lifelong therapy.
Potential Side Effects
- •Infusion reactions very common
- •IgG antibodies
- •Respiratory distress
- •Requires premedication and monitoring
Always consult with a healthcare professional before starting any peptide therapy.